Sarepta Therapeutics, Inc. SRPT Business Segments — Other Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s business segments — other research and development expense?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — other research and development expense of $18.67M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s business segments — other research and development expense changed year-over-year?
- Sarepta Therapeutics, Inc.'s business segments — other research and development expense decreased by 34.4% year-over-year, from $28.47M to $18.67M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — other research and development expense?
- Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — other research and development expense has grown at a -2.9% compound annual growth rate (CAGR), from $117.17M to $107.35M.
- What does business segments — other research and development expense mean?
- Encompasses miscellaneous research and development expenditures not captured in specific clinical trial categories, such as early-stage discovery or platform research. It tracks the ongoing investment in the segment's long-term innovation capabilities.